Needham upgraded Collegium Pharmaceutical (COLL) to Buy from Hold with a $46 price target The analyst cites the company’s topline and ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...

Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in ...

Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...